

## Cortical white-matter microstructure in schizophrenia

### Diffusion imaging study

N. ANDREONE, M. TANSELLA, R. CERINI, A. VERSACE, G. RAMBALDELLI,  
C. PERLINI, N. DUSI, L. PELIZZA, M. BALESTRIERI, C. BARBUI, M. NOSÈ,  
A. GASPARINI and P. BRAMBILLA

**Background** Several, although not all, of the previous small diffusion-weighted imaging (DWI) studies have shown cortical white-matter disruption in schizophrenia.

**Aims** To investigate cortical white-matter microstructure with DWI in a large community-based sample of people with schizophrenia.

**Method** Sixty-eight people with schizophrenia and 64 healthy controls underwent a session of DWI to obtain the apparent diffusion coefficient (ADC) of white-matter water molecules. Regions of interest were placed in cortical lobes.

**Results** Compared with controls, the schizophrenia group had significantly greater ADCs in frontal, temporal and occipital white matter (analysis of covariance,  $P < 0.05$ ).

**Conclusions** Our findings confirm the presence of cortical white-matter microstructure disruption in frontal and temporo-occipital lobes in the largest sample of people with schizophrenia thus far studied with this technique. Future brain imaging studies, together with genetic investigations, should further explore white-matter integrity and genes encoding myelin-related protein expression in people with first-episode schizophrenia and those at high risk of developing the disorder.

**Declaration of interest** None.

Diffusion-weighted imaging (DWI) is a relatively new technique capable of examining molecular water mobility in brain tissue by providing the apparent diffusion coefficient (ADC) of water molecules (Taylor *et al*, 2004), particularly in white matter, a highly organised tissue where water diffusion is restricted. The ADC is the critical measure for a detailed investigation of white-matter integrity and inferences can be drawn from it on white-matter microstructure, organisation and cytoarchitecture, which cannot be visualised using conventional magnetic resonance imaging (Basser, 2002). When brain tissue is disrupted, such as in neurological disorders involving white matter (for example multiple sclerosis), the ADC is abnormally increased (Nusbaum *et al*, 2000; Rovaris *et al*, 2002). Recently DWI has been used to explore white matter in schizophrenia, since this tissue has been suggested to have a major role in the pathophysiology of this disorder (Keshavan, 1999; Keshavan *et al*, 2005). Indeed, white-matter changes may alter intra-hemispheric connectivity and functional brain lateralisation in people with schizophrenia (Falkai *et al*, 1995; DeLisi *et al*, 1997; Crow, 1998; Brambilla *et al*, 2005), potentially sustaining cognitive deficits. Several DWI studies conducted in recent years have consistently shown cortical white-matter disruptions (Taylor *et al*, 2004), although not all investigations have done so (Steel *et al*, 2001; Foong *et al*, 2002; see Table DS1 to the online version of this paper). However, previous diffusion imaging reports were limited by small sample sizes.

We used DWI to investigate cortical white-matter microstructure in a large community-based sample of patients with schizophrenia recruited from the geographically defined catchment area of South Verona in Italy. Our hypothesis, based on previously published findings of disrupted white-matter integrity in schizophrenia, was that people with schizophrenia would have increased ADC values.

## METHOD

### Sample

Sixty-eight people with a DSM-IV diagnosis of schizophrenia (American Psychiatric Association, 1994) were studied (Table 1). They were recruited from the geographically defined catchment area of South Verona (100 000 inhabitants) and treated by the South Verona community-based mental health service and by other clinics reporting to the South Verona Psychiatric Care Register (Amadeo *et al*, 1997; Tansella & Buriti, 2003). Diagnoses of schizophrenia were obtained using the Item Group Checklist of the Schedule for Clinical Assessment in Neuropsychiatry (IGC-SCAN; World Health Organization, 1992) and confirmed with the clinical consensus of two staff psychiatrists. The IGC-SCAN assessments were completed by two trained research clinical psychologists (C.P., L.P.) with extensive experience in using the SCAN instrument. They completed at least ten IGC-SCAN ratings with a senior investigator trained in SCAN assessment, after having conducted several IGC-SCAN assessments. Successively, reliability was checked in a further ten assessments with the senior investigator, masked to the results. Similar diagnoses were obtained for at least eight out of ten IGC-SCAN assessments. Moreover, the psychopathological item groups completed by the two raters were compared in order to discuss any major symptom discrepancies. In addition, we regularly assured reliability of the IGC-SCAN diagnoses by holding consensus meetings with treating psychiatrists and a senior investigator. It is noteworthy that the Italian version of the SCAN was edited by our group (World Health Organization, 1996) and that our investigators attended specific training courses held by an official trainer in order to learn how to administer the IGC-SCAN. Subsequently, diagnoses of schizophrenia were corroborated with the clinical consensus of two staff psychiatrists, according to DSM-IV criteria. Patients with a comorbid psychiatric disorder, alcohol or substance misuse within the 6 months preceding the study, a history of traumatic head injury with loss of consciousness, or epilepsy or other neurological diseases were excluded. All but two patients were receiving antipsychotic medication at the time of imaging. Specifically, 22 patients were taking typical antipsychotic drugs (13 haloperidol, 3 chlorpromazine, 2 fluphenazine,

**Table 1** Socio-demographic and clinical variables of the sample

	Control group (n=64)	Schizophrenia group (n=68)
Age, years: mean (s.d.)	40.70 (11.16)	41.39 (11.68)
Males/females, n	34/30	39/29
Right-handed	60	64
Ethnicity, %		
White	100	100
Education, n		
Primary or secondary school	22	51***
High school	15	15
First degree or professional school	27	2
Clinical variables: mean (s.d.)		
Age at onset, years		27.46 (9.48)
Length of illness, years		14.40 (11.12)
Number of hospitalisations		3.79 (6.09)
Lifetime antipsychotic treatment, years		12.83 (10.76)
BPRS score		
Total		45.38 (16.96)
Negative symptom score		9.08 (3.13)
Positive symptom score		11.74 (6.68)

Brief Psychiatric Rating Scale.  
\*\*\* $\chi^2=33.31$ ,  $P < 0.001$ .

2 clotiapine, 1 thioridazine, 1 zuclopenthixol) and 44 on atypical antipsychotic medication (25 on olanzapine, 9 on clozapine, 8 on risperidone, 2 on quetiapine). Patients' clinical information was retrieved from psychiatric interviews, the attending psychiatrist and medical charts. Clinical symptoms were characterised using the 24-item Brief Psychiatric Rating Scale (BPRS; Ventura *et al*, 2000), which was administered by two trained research clinical psychologists (C.P., L.P.). The reliability of the BPRS ratings was established and monitored using similar procedures to those used for the IGC-SCAN.

Sixty-four people were recruited to constitute a healthy control group (Table 1). They had no DSM-IV Axis I disorder, as determined by an interview modified from the Structured Clinical Interview – DSM-IV Axis I Disorders, non-patient version (Spitzer & Williams, 1988), no history of psychiatric disorder in a first-degree relative, no history of alcohol or substance misuse and no current major medical illness. Members of the control group were hospital or university staff volunteers or patients undergoing magnetic resonance imaging (MRI) for dizziness without evidence of central nervous system abnormalities on the scan, as reviewed by the neuroradiologist

(R.C.); their dizziness was due to benign paroxysmal positional vertigo or to non-toxic labyrinthitis. Control group participants were scanned only after a full medical history and general neurological, otoscopic and physical examinations, and after they had completely recovered from their dizziness. None was taking any medication at the time of participation, including drugs for nausea or vertigo.

This research study was approved by the biomedical ethics committee of the Azienda Ospedaliera of Verona. All individuals provided signed informed consent, after having understood all issues involved in study participation.


### Imaging procedure

The MRI scans were acquired with a 1.5 T Siemens Magnetom Symphony Maestro Class, Syngo MR 2002B (<http://www.medical.siemens.com>). A standard head coil was used for radiofrequency transmission and reception of the MR signal and restraining foam pads were used to minimise head motion. First,  $T_1$ -weighted images were obtained to verify the participant's head position and the image quality: repetition time (TR) 450 ms, time to echo (TE) 14 ms, flip angle  $90^\circ$ , field of view (FOV)

230 mm  $\times$  230 mm, 18 slices, slice thickness=5 mm, matrix size 384 mm  $\times$  512 mm. Proton density  $T_2$ -weighted images were then acquired (TR= 2500 ms, TE=24/121 ms, flip angle  $180^\circ$ , FOV 230 mm  $\times$  230 mm, 20 slices, slice thickness 5 mm, matrix size 410  $\times$  512), according to an axial plane parallel to the anterior-posterior commissures (AC-PC), for clinical neurodiagnostic evaluations (exclusion of focal lesions). Subsequently, diffusion-weighted echoplanar images were acquired in the axial plane parallel to the AC-PC line (TR=3200 ms, TE=94 ms, FOV 230 mm  $\times$  230 mm, 20 slices, slice thickness 5 mm with 1.5 mm gap, matrix size 128 mm  $\times$  128 mm; these parameters were the same for  $b=0$ ,  $b=1000$  and the ADC maps) and in the coronal plane from the frontal to the occipital lobes (TR=5000 ms, TE=94 ms, FOV 230 mm  $\times$  230 mm, 30 slices, slice thickness 4 mm with 0.4 mm gap, matrix size 128  $\times$  128; these parameters were the same for  $b=0$ ,  $b=1000$  and the ADC maps). Specifically, diffusion-weighted MRI was performed in three orthogonal directions during all sequences.

### Image analyses

The apparent diffusion coefficients of water molecules for cortical white matter were detected by using software developed in-house written in MatLab version 7 (The Mathworks, Natick, Massachusetts, USA). The ADCs were obtained by placing, bilaterally, circular regions of interest in the frontal, temporal, parietal and occipital cortex on the non-diffusion-weighted ( $b=0$ ) echoplanar images in reference to standard brain atlases (Jackson & Duncan, 1996; Patel & Friedman, 1997) and according to previous studies (Sun *et al*, 2003; Wolkin *et al*, 2003; Kumra *et al*, 2004; Kitamura *et al*, 2005; Fig. 1). The regions of interest were then automatically transferred to the corresponding maps to obtain the ADCs. The ADC maps were obtained from the diffusion images with  $b=1000$ , according to the equation  $b_{ADC}=\ln[A(b)/A(0)]$ , where  $A(b)$  is the measured echo magnitude,  $b$  is the measure of diffusion weighting and  $A(0)$  is the echo magnitude without diffusion gradient applied (Basser, 2002). The resulting ADC was expressed in units of  $10^{-5}$  mm<sup>2</sup>/s. A trained rater (N.A.), masked to group assignment and patient identity, measured all scans. The intraclass correlation coefficients, which were calculated by having two independent



**Fig. 1** Circular regions of interest were placed in cortical white matter on the  $b=0$  echoplanar images, and then automatically transferred to apparent diffusion coefficient (ADC) maps (A, frontal lobes; B, temporal lobes; C, parietal lobes; D, occipital lobes).

raters (N.A. and A.V.) trace ten training scans were higher than 0.90.

### Anatomical landmarks

#### Frontal cortex

Regions of interest were positioned in the axial slice at the level of the genu of corpus callosum (standardised at  $43.5 \text{ mm}^2$ ), then in the inferior slice (standardised at  $43.5 \text{ mm}^2$ ) and in the two superior slices (standardised at  $84.4 \text{ mm}^2$ ), posteriorly and medially to the frontal horns of the lateral ventricles.

#### Parietal cortex

Regions of interest (standardised at  $84.4 \text{ mm}^2$ ) were placed in the axial slice when the lateral ventricles first disappeared and in the superior slice, posteriorly to the postcentral sulcus.

#### Temporal cortex

Regions of interest (standardised at  $43.5 \text{ mm}^2$ ) were positioned in the axial slice at the level of the lateral fissure and in the inferior slice, posteriorly and laterally to the lateral fissure.

#### Occipital cortex

Regions of interest (standardised at  $43.5 \text{ mm}^2$ ) were placed in the two inferior axial slices where the occipital horns of the lateral ventricles become visible, posteriorly to the occipital horns.

### Statistical analyses

All analyses were conducted using the Statistical Package for the Social Sciences version 11.0 for Windows and the two-tailed statistical significance level was set at  $P < 0.05$ . Analysis of covariance (ANCOVA) with age and gender as covariates was performed to compare white-matter ADCs between the schizophrenia group and the control group. Pearson's correlation and partial correlation analyses controlled for age were used to examine possible association between age and clinical variables respectively, and ADC measures.

## RESULTS

Compared with the control group, the participants with schizophrenia had significantly greater apparent diffusion coefficients for frontal, temporal and occipital

white matter (Table 2), even when taking educational level into consideration (right and left frontal ADCs,  $P=0.09$ ,  $P=0.12$ ; right and left temporal ADCs,  $P=0.006$ ,  $P=0.009$ ; right and left occipital ADCs,  $P=0.006$ ,  $P=0.002$ , respectively; ANCOVA, age, gender and educational level as covariates). Similar results were found when the schizophrenia group was compared separately with control participants recruited from hospital and university staff ( $n=33$ ) (left frontal ADCs,  $P=0.14$ ; temporal ADCs:  $P < 0.001$ , occipital ADCs,  $P < 0.003$ ) and with control participants who had been treated for dizziness ( $n=31$ ) (right frontal ADCs,  $P=0.07$ ; temporal ADCs,  $P=0.01$ ; occipital ADCs,  $P \leq 0.01$ ) (ANCOVA; age and gender as covariates). Also, no significant difference for any ADC measure was found between the two control subgroups (ANCOVA; age and gender as covariates,  $P > 0.05$ ).

The ADC measures were still greater in the schizophrenia group than in the combined control group when both groups were stratified by gender, both in men (left frontal ADCs,  $P=0.04$ ; temporal ADCs,  $P < 0.001$ , occipital ADCs,  $P < 0.002$ ) and women (right temporal ADCs,  $P=0.12$ ; left

**Table 2** Apparent diffusion coefficient measures for cortical white matter.

	ADC, 10 <sup>-5</sup> mm <sup>2</sup> /s: mean (s.d.)		F	P
	Control group (n=64)	Schizophrenia group (n=68)		
Right frontal cortex	75.31 (3.43)	76.48 (4.34)	2.98	0.08
Left frontal cortex	72.17 (3.86)	73.59 (4.89)	4.10	0.04
Right temporal cortex	75.20 (4.37)	78.71 (5.66)	15.91	<0.001
Left temporal cortex	75.23 (4.67)	78.88 (5.63)	16.83	<0.001
Right parietal cortex	71.04 (4.52)	70.63 (3.80)	0.22	0.64
Left parietal cortex	72.86 (3.95)	73.27 (3.27)	0.60	0.44
Right occipital cortex	77.47 (4.43)	80.94 (6.37)	12.98	<0.001
Left occipital cortex	75.91 (3.70)	79.26 (5.14)	17.71	<0.001

ADC, apparent diffusion coefficient.

temporal ADCs,  $P=0.03$ ; right occipital ADCs,  $P=0.06$ ; left occipital ADCs,  $P=0.01$ ) (Mann–Whitney  $U$ -test).

Age was significantly and directly correlated with left temporal ADC measures in the control group ( $r=0.28$ ,  $P=0.02$ ) but not in the schizophrenia group ( $r=0.16$ ,  $P=0.18$ ). No significant association was shown between age and other ADC values (Pearson's correlation,  $P>0.05$ ) or between clinical variables (age at onset, length of illness, number of hospitalisations, BPRS scores, antipsychotic lifetime treatment) and white matter ADCs (partial correlation controlled for age,  $P>0.05$ ). Furthermore, no significant difference for any ADC value was observed between patients treated with typical antipsychotic drugs ( $n=22$ ) and those treated with atypical antipsychotics ( $n=44$ ) (Mann–Whitney  $U$ -test,  $P>0.05$ ). Also, patients with severe illness (BPRS  $>41$ ;  $n=37$ ) did not differ significantly on any ADC measure compared with patients with mild-to-moderate illness (BPRS  $\leq 41$ ;  $n=31$ ) (Mann–Whitney  $U$ -test,  $P>0.05$ ). A BPRS total score of 41 was chosen as the cut-off level for mild or moderate illness, indicated by Leucht *et al* (2005).

## DISCUSSION

This study found widespread regional white-matter disruption in schizophrenia, as shown by higher ADCs in frontal, temporal and occipital lobes. To our knowledge, this is the largest study to show disrupted white-matter cytoarchitecture in schizophrenia (Kanaan *et al*, 2005). Consistently, impairments of cortical white-matter

integrity have been found in people with schizophrenia by a number of prior small diffusion imaging studies (Kubicki *et al*, 2007, see online Table DS1). Specifically, abnormally increased water diffusion coefficients or abnormally decreased fractional anisotropy have been found in at least ten prior investigations of frontal lobes (Buchsbaum *et al*, 1998; Ardekani *et al*, 2003; Minami *et al*, 2003; Kumra *et al*, 2004; Wang *et al*, 2004; Kitamura *et al*, 2005; Kubicki *et al*, 2005a; Szeszko *et al*, 2005; Hao *et al*, 2006; Shin *et al*, 2006) and in temporo-occipital lobes (Lim *et al*, 1999; Agartz *et al*, 2001; Ardekani *et al*, 2003, 2005; Minami *et al*, 2003; Kumra *et al*, 2004; Kubicki *et al*, 2005a; Szeszko *et al*, 2005; Hao *et al*, 2006; Shin *et al*, 2006). However, some studies report preserved integrity of white matter in schizophrenia (Steel *et al*, 2001; Foong *et al*, 2002; Kubicki *et al*, 2002). Both ADC and fractional anisotropy are considered as complementary indices of white-matter microstructure organisation, providing evidence of disruption when increased and decreased respectively (Taylor *et al*, 2004). In our study, we did not report fractional anisotropy because the diffusion tensor sequence was not collected. Specifically, the ADC image provides a relative presentation of the diffusion coefficient in each pixel within the image, where low and high intensity values indicate respectively low and high diffusion (Basser, 2002). Abnormalities in cortical white matter may lead to impaired connection, which may ultimately alter the speed, quantity and/or quality of intrahemispheric communication, relevant to cognitive disturbances reported in schizophrenia (Krabbendam *et al*,

2005). This may be a result of reduced axonal density or myelination. Indeed, oligodendrocytes, which have the potential to influence myelination and synaptic transmission, have been found to be functionally abnormal in schizophrenia (Hof *et al*, 2002; Davis *et al*, 2003; Bartzokis & Altshuler, 2005). None the less, several factors may contribute to explain increased water white-matter diffusion, such as less dense packing of fibres, disruption of internal axonal integrity (reduced intra-axonal microtubular density), reduced degree of myelination or variation in membrane permeability to water. However, since white-matter is mostly composed of myelinated axons, the density of axonal membranes and myelin seem to play the major part (Beaulieu & Allen, 1994; Giedd, 2004).

Several earlier diffusion imaging studies reported frontal, temporal and occipital white-matter alterations within regions of interest identified by visual inspection of the individual anatomy, as in our method (Steel *et al*, 2001; Hoptman *et al*, 2002; Minami *et al*, 2003; Wolkin *et al*, 2003; Kumra *et al*, 2004; Kitamura *et al*, 2005). In particular, we examined the middle and inferior frontal white-matter regions, which have been shown to be functionally altered in schizophrenia (Shenton *et al*, 2001), potentially sustaining executive function deficits (MacDonald *et al*, 2005; Brambilla *et al*, 2007). Moreover, temporal regions of interest were positioned in the medial temporal white matter regions, which are involved in modulating language domain in humans and are likely to have a key role in language abnormalities in schizophrenia (Seidman *et al*, 2003; Antonova *et al*, 2004). Finally, the occipital regions of interest were placed in medial occipital areas, which have been shown to be altered in schizophrenia by other diffusion imaging studies (Lim *et al*, 1999; Agartz *et al*, 2001; Ardekani *et al*, 2003, 2005; Minami *et al*, 2003; Kumra *et al*, 2004). Furthermore, abnormalities in early-stage visual processing in schizophrenia have recently been shown, possibly contributing to higher-level cognitive deficits (Butler *et al*, 2005; Schechter *et al*, 2005). Therefore, our findings suggest that frontal and temporo-occipital white-matter disruption may in part support cognitive and language deficits in schizophrenia.

Taken together, these brain imaging findings indicate that cortical white-matter microstructure is disrupted in schizophrenia. Moreover, these results may be supported

by post-mortem studies showing a quantitative reduction in white matter cells (Akbarian *et al*, 1996; Uranova *et al*, 2004). In particular, reduced expression of myelin and oligodendrocyte-related genes and proteins has been shown in schizophrenia, suggesting oligodendrocyte dysfunction (Flynn *et al*, 2003; Hof *et al*, 2003; Tkachev *et al*, 2003; Chambers & Perrone-Bizzozero, 2004). Specifically, neuregulin 1 (*NRG1*), a candidate gene for schizophrenia (Stefansson *et al*, 2002; Tosato *et al*, 2005; Williams *et al*, 2005), has been shown to have a key role in oligodendrocyte development and proliferation (Marchionni *et al*, 1993; Vartanian *et al*, 1999; Liu *et al*, 2001). Therefore, altered expression of *NRG1* or other myelination-related genes may potentially result in abnormal oligodendrocyte function or myelination in schizophrenia (Hakak *et al*, 2001; O'Donovan *et al*, 2003). However, it remains to be elucidated whether cortical white-matter impairment mostly reflects brain maldevelopment or neurodegeneration. In particular, it would be of great interest to understand how and when the white-matter disruption in schizophrenia relates to the physiological processes of white-matter maturation (Bartzokis, 2002; Hafner, 2004; Harrison, 2004; Bresnahan *et al*, 2005). Indeed, recent reports suggest that intracortical myelination increases during adulthood, reaching its peak during the fifth decade of life, particularly in the frontal and temporal lobes (Bartzokis *et al*, 2003), in a constant state of well-regulated structural and functional change. Affected myelination in schizophrenia, which may itself be due to multiple genetic and environmental factors, may contribute to alter this temporally expanded view of brain white-matter development from adolescence until middle age. As proposed by Bartzokis, this would ultimately result in dysregulation of the temporal synchronous development of widely distributed neural networks in schizophrenia, being manifested in the heterogeneity of symptoms and cognitive impairments (Bartzokis, 2002). Interestingly, white-matter alterations (particularly of corpus callosum) and abnormal down-regulation of oligodendrocyte and myelination genes have been demonstrated in bipolar affective disorder as well as in schizophrenia (Brambilla *et al*, 2003, 2004; Tkachev *et al*, 2003). This sustains the notion that the two disorders may have similar white-matter pathophysiological pathways. Future brain imaging studies

together with genetic investigations should further explore white-matter integrity and genes encoding myelin-related protein expression in people with first-episode schizophrenia and possibly bipolar affective disorder, and in the populations at high risk of developing these disorders.

Interestingly, we found a significant direct correlation between age and left temporal ADC values in the control group which was not present in the schizophrenia group. This is consistent with a recent investigation showing in controls, but not in patients, a significant negative effect of age on the integrity of the left superior longitudinal fasciculus, which connects the frontal and temporal cortex (Jones *et al*, 2006). Also, age-related decline of cerebral white-matter coherence in humans, which may represent subtle structural white-matter changes with normal ageing, has been demonstrated by diffusion imaging studies (Engelter *et al*, 2000; Pfefferbaum *et al*, 2000; O'Sullivan *et al*, 2001; Sullivan *et al*, 2001). Thus, as a speculative interpretation, it is possible that the effects of physiological ageing on white matter cannot be seen in schizophrenia owing to the presence, since early adolescence, of abnormal neurodevelopment and cytoarchitectural organisation of cortical white matter, particularly in the temporal region (Pantelis *et al*, 2005).

No significant association between ADC values and any clinical variable was found in our study, consistent with several prior reports exploring correlations between diffusion measures and clinical features in schizophrenia (Steel *et al*, 2001; Kumra *et al*, 2004, 2005; Jones *et al*, 2005; Kubicki *et al*, 2005a; Kitamura *et al*, 2005; Szesko *et al*, 2005). This suggests that cortical white-matter disruption in schizophrenia is not a secondary effect of chronicity, medication or psychopathology but is potentially related to the core pathophysiology of the disease. However, it should be mentioned that two small studies have found increased white-matter alterations in people with schizophrenia with more severe negative symptoms in the right insula (Shin *et al*, 2006) and the inferior frontal region (Wolkin *et al*, 2003). However, the latter group also showed a relationship between impulsivity/aggression and altered white-matter microstructure in the right inferior frontal region and insula in men with schizophrenia (Hoptman *et al*, 2002, 2004). Therefore, the correlation between white-matter cytoarchitecture and

clinical symptoms in schizophrenia is still controversial and needs further investigation in large samples.

It should be noted that our schizophrenia sample mostly comprised treated patients with chronic illness, thus it is not clear whether white-matter disruption preceded the onset of the illness or appeared subsequently as a result of illness course or psychotropic treatment. However, length of illness or antipsychotic lifetime administration did not significantly affect ADC values, suggesting that cortical white-matter abnormalities may not be related to illness or medication. Also, we recruited a relatively larger number of participants than prior diffusion imaging studies, with a good match between those in the schizophrenia and control groups, providing adequate power. Part of our control group was selected from individuals undergoing MRI scanning for dizziness, which may represent a methodological limitation. However, these participants were fully recovered at the time of scanning and had no evidence of central nervous system abnormalities on the scan. Finally, no particular white-matter tracts could be detected with our approach, such as the uncinate or the arcuate fasciculi which form specific temporo- and parieto-frontal connections (Burns *et al*, 2003; Kubicki *et al*, 2005b; Jones *et al*, 2006).

In conclusion, altered cortical white-matter microstructure in schizophrenia has been replicated in this large study, particularly in frontal and temporo-occipital lobes. Hypothetically, abnormal myelination due to oligodendrocyte dysfunction might account for these findings. This might potentially affect intrahemispheric communication and ultimately lead to the cognitive disturbances seen in people with schizophrenia.

## ACKNOWLEDGEMENTS

We thank Dr Sarah Tosato, MD, for helpful comments on the earlier version of this manuscript. This work was partly supported by grants from the American Psychiatric Institute for Research and Education (APIRE/AstraZeneca Young Minds in Psychiatry Award) and from the Italian Ministry for Education, University and Research (PRIN 2005068874) to P.B.

## REFERENCES

Agartz, I., Andersson, J. L. & Skare, S. (2001) Abnormal brain white matter in schizophrenia: a

- diffusion tensor imaging study. *NeuroReport*, **12**, 2251–2254.
- Akbarian, S., Kim, J. J., Potkin, S. G., et al (1996)** Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. *Archives of General Psychiatry*, **53**, 425–436.
- Amaddeo, F., Beecham, J., Bonizzato, P., et al (1997)** The use of a case register to evaluate the costs of psychiatric care. *Acta Psychiatrica Scandinavica*, **95**, 189–198.
- American Psychiatric Association (1994)** *Diagnostic and Statistical Manual of Mental Disorders* (4th edn) (DSM–IV). APA.
- Antonova, E., Sharma, T., Morris, R., et al (2004)** The relationship between brain structure and neurocognition in schizophrenia: a selective review. *Schizophrenia Research*, **70**, 117–145.
- Ardekani, B. A., Nierenberg, J., Hoptman, M. J., et al (2003)** MRI study of white matter diffusion anisotropy in schizophrenia. *NeuroReport*, **14**, 2025–2029.
- Ardekani, B. A., Bappal, A., D'Angelo, D., et al (2005)** Brain morphometry using diffusion-weighted magnetic resonance imaging: application to schizophrenia. *NeuroReport*, **16**, 1455–1459.
- Bartzokis, G. (2002)** Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. *Neuropsychopharmacology*, **27**, 672–683.
- Bartzokis, G. & Altshuler, L. (2005)** Reduced intracortical myelination in schizophrenia. *American Journal of Psychiatry*, **162**, 1229–1230.
- Bartzokis, G., Nuechterlein, K. H., Lu, P. H., et al (2003)** Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. *Biological Psychiatry*, **53**, 412–421.
- Basser, P. J. (2002)** Diffusion and diffusion tensor MR imaging. In *Magnetic Resonance Imaging of the Brain and Spine*. (3rd edn) (ed. S.W. Atlas), pp. 197–214. Lippincott Williams & Wilkins.
- Beaulieu, C. & Allen, P. S. (1994)** Determinants of anisotropic water diffusion in nerves. *Magnetic Resonance Medicine*, **31**, 394–400.
- Brambilla, P., Nicoletti, M. A., Sassi, R. B., et al (2003)** Magnetic resonance imaging study of corpus callosum abnormalities in patients with bipolar disorder. *Biological Psychiatry*, **54**, 1294–1297.
- Brambilla, P., Nicoletti, M., Sassi, R. B., et al (2004)** Corpus callosum signal intensity in patients with bipolar and unipolar disorder. *Journal of Neurology, Neurosurgery and Psychiatry*, **75**, 221–225.
- Brambilla, P., Cerini, R., Gasparini, A., et al (2005)** Investigation of corpus callosum in schizophrenia with diffusion imaging. *Schizophrenia Research*, **79**, 201–210.
- Brambilla, P., MacDonald, A. W., Sassi, R. B., et al (2007)** Context processing performance in bipolar disorder patients. *Bipolar Disorders*, **9**, 230–237.
- Bresnahan, M., Schaefer, C. A., Brown, A. S., et al (2005)** Prenatal determinants of schizophrenia: what we have learned thus far? *Epidemiologia e Psichiatria Sociale*, **14**, 194–197.
- Buchsbaum, M. S., Tang, C. Y., Peled, S., et al (1998)** MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. *NeuroReport*, **9**, 425–430.
- Burns, J., Job, D., Bastin, M. E., et al (2003)** Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. *British Journal of Psychiatry*, **182**, 439–443.
- Butler, P. D., Zemon, V., Schechter, I., et al (2005)** Early-stage visual processing and cortical amplification deficits in schizophrenia. *Archives of General Psychiatry*, **62**, 495–504.
- Chambers, J. S. & Perrone-Bizzozero, N. I. (2004)** Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. *Neurochemical Research*, **29**, 2293–2302.
- Crow, T. J. (1998)** Schizophrenia as a transcallosal misconnection syndrome. *Schizophrenia Research*, **30**, 111–114.
- Davis, K. L., Stewart, D. G., Friedman, J. I., et al (2003)** White matter changes in schizophrenia: evidence for myelin-related dysfunction. *Archives of General Psychiatry*, **60**, 443–456.
- DeLisi, L. E., Sakuma, M., Kushner, M., et al (1997)** Anomalous cerebral asymmetry and language processing in schizophrenia. *Schizophrenia Bulletin*, **23**, 255–271.
- Engelter, S. T., Provenzale, J. M., Petrella, J. R., et al (2000)** The effect of aging on the apparent diffusion coefficient of normal-appearing white matter. *American Journal of Roentgenology*, **175**, 425–430.
- Falkai, P., Bogerts, B., Schneider, T., et al (1995)** Disturbed planum temporale asymmetry in schizophrenia. A quantitative post-mortem study. *Schizophrenia Research*, **14**, 161–176.
- Flynn, S. W., Lang, D. J., Mackay, A. L., et al (2003)** Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. *Molecular Psychiatry*, **8**, 811–820.
- Foong, J., Symms, M. R., Barker, G. J., et al (2002)** Investigating regional white matter in schizophrenia using diffusion tensor imaging. *NeuroReport*, **13**, 333–336.
- Giedd, J. N. (2004)** Structural magnetic resonance imaging of the adolescent brain. *Annals of the New York Academy of Sciences*, **1021**, 77–85.
- Hafner, H. (2004)** Schizophrenia: still Kraepelin's dementia praecox? *Epidemiologia e Psichiatria Sociale*, **13**, 99–112.
- Hakak, Y., Walker, J. R., Li, C., et al (2001)** Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proceedings of the National Academy of Sciences of the USA*, **98**, 4746–4751.
- Hao, Y., Liu, Z., Jiang, T., et al (2006)** White matter integrity of the whole brain is disrupted in first-episode schizophrenia. *NeuroReport*, **17**, 23–26.
- Harrison, G. (2004)** Trajectories of psychosis: towards a new social biology of schizophrenia. *Epidemiologia e Psichiatria Sociale*, **13**, 152–157.
- Hof, P. R., Haroutunian, V., Copland, C., et al (2002)** Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. *Neurochemical Research*, **27**, 1193–1200.
- Hof, P. R., Haroutunian, V., Friedrich, V. L., et al (2003)** Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. *Biological Psychiatry*, **53**, 1075–1085.
- Hoptman, M. J., Volavka, J., Johnson, G., et al (2002)** Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. *Biological Psychiatry*, **52**, 9–14.
- Hoptman, M. J., Ardekani, B. A., Butler, P. D., et al (2004)** DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. *NeuroReport*, **15**, 2467–2470.
- Jackson, G. D. & Duncan, J. S. (1996)** *MRI Anatomy: A New Angle on the Brain*. Churchill Livingstone.
- Jones, D. K., Catani, M., Pierpaoli, C., et al (2005)** A diffusion tensor magnetic resonance imaging study of frontal cortex connections in very-late-onset schizophrenia-like psychosis. *American Journal of Geriatric Psychiatry*, **13**, 1092–1099.
- Jones, D. K., Catani, M., Pierpaoli, C., et al (2006)** Age effects on diffusion tensor magnetic resonance imaging tractography measures of frontal cortex connections in schizophrenia. *Human Brain Mapping*, **27**, 230–238.
- Kanaan, R. A., Kim, J. S., Kaufmann, W. E., et al (2005)** Diffusion tensor imaging in schizophrenia. *Biological Psychiatry*, **58**, 921–929.
- Keshavan, M. S. (1999)** Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. *Journal of Psychiatric Research*, **33**, 513–521.
- Keshavan, M. S., Diwadkar, V. A. & Rosenberg, D. R. (2005)** Developmental biomarkers in schizophrenia and other psychiatric disorders: common origins, different trajectories? *Epidemiologia e Psichiatria Sociale*, **14**, 188–193.
- Kitamura, H., Matsuzawa, H., Shioiri, T., et al (2005)** Diffusion tensor analysis in chronic schizophrenia. A preliminary study on a high-field (3.0T) system. *European Archives of Psychiatry and Clinical Neuroscience*, **255**, 313–318.
- Krabbedam, L., Arts, B., van Os, J., et al (2005)** Cognitive functioning in patients with schizophrenia and bipolar disorder: A quantitative review. *Schizophrenia Research*, **80**, 137–149.
- Kubicki, M., Westin, C. F., Maier, S. E., et al (2002)** Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study. *American Journal of Psychiatry*, **159**, 813–820.
- Kubicki, M., Westin, C. F., Nestor, P. G., et al (2003)** Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. *Biological Psychiatry*, **54**, 1171–1180.
- Kubicki, M., Park, H., Westin, C. F., et al (2005a)** DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. *NeuroImage*, **26**, 1109–1118.
- Kubicki, M., Westin, C. F., McCarley, R. W., et al (2005b)** The application of DTI to investigate white matter abnormalities in schizophrenia. *Annals of the New York Academy of Science*, **1064**, 134–148.
- Kubicki, M., McCarley, R., Westin, C. F., et al (2007)** A review of diffusion tensor imaging studies in schizophrenia. *Journal of Psychiatric Research*, **41**, 15–30.
- Kumra, S., Ashtari, M., McMeniman, M., et al (2004)** Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. *Biological Psychiatry*, **55**, 1138–1145.
- Kumra, S., Ashtari, M., Cervellione, K. L., et al (2005)** White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. *Journal of the American Academy of Child and Adolescent Psychiatry*, **44**, 934–941.
- Leucht, S., Kane, J. M., Kissling, W., et al (2005)** Clinical implications of Brief Psychiatric Rating Scale scores. *British Journal of Psychiatry*, **187**, 366–371.
- Lim, K. O., Hedehus, M., Moseley, M., et al (1999)** Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. *Archives of General Psychiatry*, **56**, 367–374.
- Liu, Y., Ford, B., Mann, M. A., et al (2001)** Neuregulins increase alpha7 nicotinic acetylcholine receptors and

enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. *Journal of Neuroscience*, **21**, 5660–5669.

**MacDonald, A. W., Carter, C. S., Kerns, J. G., et al (2005)** Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. *American Journal of Psychiatry*, **162**, 475–484.

**Marchionni, M. A., Goodearl, A. D., Chen, M. S., et al (1993)** Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. *Nature*, **362**, 312–318.

**Minami, T., Nobuhara, K., Okugawa, G., et al (2003)** Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. *Neuropsychobiology*, **47**, 141–145.

**Nusbaum, A. O., Tang, C. Y., Wei, T., et al (2000)** Whole-brain diffusion MR histograms differ between MS subtypes. *Neurology*, **54**, 1421–1427.

**O'Donovan, M. C., Williams, N. M. & Owen, M. J. (2003)** Recent advances in the genetics of schizophrenia. *Human Molecular Genetics*, **12**, R125–R133.

**O'Sullivan, M., Jones, D. K., Summers, P. E., et al (2001)** Evidence for 'cortical' disconnection as a mechanism of age-related cognitive decline. *Neurology*, **57**, 632–638.

**Pantelis, C., Yucel, M., Wood, S. J., et al (2005)** Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. *Schizophrenia Bulletin*, **31**, 672–696.

**Park, H. J., Westin, C. F., Kubicki, M., et al (2004)** White matter hemisphere asymmetries in healthy subjects and in schizophrenia: a diffusion tensor MRI study. *NeuroImage*, **23**, 213–223.

**Patel, V. H. & Friedman, L. (1997)** *MRI of the Brain: Normal Anatomy and Normal Variants*. Saunders.

**Pfefferbaum, A., Sullivan, E. V., Hedehus, M., et al (2000)** Age-related decline in brain white matter anisotropy measured with spatially corrected echo-planar diffusion tensor imaging. *Magnetic Resonance Medicine*, **44**, 259–268.

**Rovaris, M., Bozzali, M., Iannucci, G., et al (2002)** Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. *Archives of Neurology*, **59**, 1406–1412.

**Schechter, I., Butler, P. D., Zemon, V. M., et al (2005)** Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. *Clinical Neurophysiology*, **116**, 2204–2215.

**Seidman, L. J., Pantelis, C., Keshavan, M. S., et al (2003)** A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. *Schizophrenia Bulletin*, **29**, 803–830.

**Shenton, M. E., Dickey, C. C., Frumin, M., et al (2001)** A review of MRI findings in schizophrenia. *Schizophrenia Research*, **49**, 1–52.

**Shin, Y. W., Kwon, J. S., Ha, T. H., et al (2006)** Increased water diffusivity in the frontal and temporal

N. ANDREONE, MD, M. TANSELLA, MD, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, and Verona–Udine Brain Imaging and Neuropsychology Programme, Inter-University Centre for Behavioural Neurosciences, University of Verona; R. CERINI, MD, Department of Morphological and Biomedical Sciences, Section of Radiology, GB Rossi Hospital, University of Verona; A. VERSACE, MD, G. RAMBALDELLI, MS, C. PERLINI, PsychD, N. DUSI, MD, L. PELIZZA, PsychD, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, and Verona–Udine Brain Imaging and Neuropsychology Programme, Inter-University Centre for Behavioural Neurosciences, University of Verona; M. BALESTRIERI, MD, PhD, Verona–Udine Brain Imaging and Neuropsychology Programme, Inter-University Centre for Behavioural Neurosciences, and Department of Pathology and Experimental and Clinical Medicine, Section of Psychiatry, University of Udine; C. BARBUJ, MD, M. NOSÈ, MD, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona; A. GASPARINI, MD, Department of Morphological and Biomedical Sciences, Section of Radiology, GB Rossi Hospital, University of Verona; P. BRAMBILLA, MD, PhD, Verona–Udine Brain Imaging and Neuropsychology Programme, Inter-University Centre for Behavioural Neurosciences, and Department of Pathology and Experimental and Clinical Medicine, Section of Psychiatry, University of Udine and Scientific Institute IRCCS E. Medea, Udine, Italy

Correspondence: Dr Paolo Brambilla, Dipartimento di Patologia e Medicina Clinica e Sperimentale, Cattedra di Psichiatria, Policlinico Universitario, Via Colugna 50, 33100 Udine, Italy. Tel: +39 0432 55 9494; fax: +39 0432 54 5526; email: paolo.brambilla@uniud.it

(First received 21 December 2005, final revision 12 January 2007, accepted 24 January 2007)

cortices of schizophrenic patients. *NeuroImage*, **30**, 1285–1291.

**Spitzer, R. L. & Williams, D. (1988)** *Structured Clinical Interview for Diagnoses – Nonpatient Version*. New York State Psychiatric Institute.

**Steel, R. M., Bastin, M. E., McConnell, S., et al (2001)** Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (IH MRS) in schizophrenic subjects and normal controls. *Psychiatry Research*, **106**, 161–170.

**Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., et al (2002)** Neuregulin I and susceptibility to schizophrenia. *American Journal of Human Genetics*, **71**, 877–892.

**Sullivan, E. V., Adalsteinsson, E., Hedehus, M., et al (2001)** Equivalent disruption of regional white matter microstructure in ageing healthy men and women. *NeuroReport*, **12**, 99–104.

**Sun, Z., Wang, F., Cui, L., et al (2003)** Abnormal anterior cingulum in patients with schizophrenia: a diffusion tensor imaging study. *NeuroReport*, **14**, 1833–1836.

**Szeszko, P. R., Ardekani, B. A., Ashtari, M., et al (2005)** White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. *American Journal of Psychiatry*, **162**, 602–605.

**Tansella, M. & Burti, L. (2003)** Integrating evaluative research and community-based mental health care in Verona, Italy. *British Journal of Psychiatry*, **183**, 167–169.

**Taylor, W. D., Hsu, E., Krishnan, K. R., et al (2004)** Diffusion tensor imaging: background, potential, and utility in psychiatric research. *Biological Psychiatry*, **55**, 201–207.

**Tkachev, D., Mimmack, M. L., Ryan, M. M., et al (2003)** Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet*, **362**, 798–805.

**Tosato, S., Dazzan, P. & Collier, D. (2005)** Association between the neuregulin I gene and schizophrenia: a systematic review. *Schizophrenia Bulletin*, **31**, 613–617.

**Uranova, N. A., Vostrikov, V. M., Orlovskaya, D. D., et al (2004)** Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. *Schizophrenia Research*, **67**, 269–275.

**Vartanian, T., Fischbach, G. & Miller, R. (1999)** Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. *Proceedings of the National Academy of Sciences of the USA*, **96**, 731–735.

**Ventura, J., Nuechterlein, K. H., Subotnik, K. L., et al (2000)** Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. *Psychiatry Research*, **97**, 129–135.

**Wang, F., Sun, Z., Cui, L., et al (2004)** Anterior cingulum abnormalities in male patients with schizophrenia determined through diffusion tensor imaging. *American Journal of Psychiatry*, **161**, 573–575.

**Williams, N. M., O'Donovan, M. C. & Owen, M. J. (2005)** Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? *Schizophrenia Bulletin*, **31**, 800–805.

**Wolkin, A., Choi, S. J., Szilagyi, S., et al (2003)** Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. *American Journal of Psychiatry*, **160**, 572–574.

**World Health Organization (1992)** *Schedules for Clinical Assessment in Neuropsychiatry*. WHO.

**World Health Organization (1996)** *Schede di Valutazione Clinica in Neuropsichiatria*. SCAN 2.1. Il Pensiero Scientifico Editore.